Bayer
Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms
Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer
Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer
Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER
Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes
Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
Bayer Announces 150 Job Cuts in Basel, Switzerland, Amid Global Restructuring
Bayer layoffs, Basel, Switzerland, consumer health hub, job cuts, restructuring
Bayer Pharma’s Overhaul Not Slowing Down Deal Making, Says BD Chief
Bayer Pharma, deal making, group overhaul, biotech, pharmaceutical industry
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry
Bayer’s Transformation Accelerates with 3,200 Job Cuts in 2024
Bayer, transformation, job cuts, 2024, Bill Anderson, pharmaceutical industry